How to Prescribe Cefepime for Paraplegia with UTI
For a paraplegic patient with UTI, prescribe cefepime 1-2 g IV every 12 hours for uncomplicated UTI or 2 g IV every 12 hours for severe/complicated UTI, with mandatory renal function assessment and dose adjustment if creatinine clearance is ≤60 mL/min to prevent life-threatening neurotoxicity. 1
Dosing Algorithm
Step 1: Assess Severity and Route
- Mild to moderate UTI: 0.5-1 g IV every 12 hours for 7-10 days 1
- Severe or complicated UTI: 2 g IV every 12 hours for 10 days 1
- If sepsis present: 2 g IV every 8 hours (per IDSA 2025 guidelines for fourth-generation cephalosporins in septic cUTI) 2
Paraplegic patients typically have complicated UTI (cUTI) due to neurogenic bladder dysfunction, so the higher dosing regimen is generally appropriate 3.
Step 2: Mandatory Renal Function Assessment
This is critical and non-negotiable. Cefepime causes severe neurotoxicity (encephalopathy, seizures, myoclonus, nonconvulsive status epilepticus) in patients with renal impairment who receive unadjusted doses 1. Most neurotoxicity cases occurred in patients with unrecognized renal dysfunction 1.
- Calculate creatinine clearance before first dose
- If CrCL ≤60 mL/min: Dose adjustment is mandatory 1
- Monitor for neurotoxicity signs: confusion, hallucinations, altered consciousness, myoclonus 1
Step 3: Administration Details
- Infuse IV over 30 minutes 1
- Duration: 7-10 days for cUTI 1
- Do not use oral step-down therapy in paraplegic patients with neurogenic bladder unless infection source is controlled and patient is clinically stable 2
Critical Warnings Specific to This Population
Neurotoxicity Risk
Paraplegic patients may have:
- Unrecognized renal impairment from chronic urinary stasis
- Recurrent antibiotic exposure increasing risk
- If any neurologic symptoms develop, discontinue cefepime immediately 1
- Symptoms are usually reversible after discontinuation or hemodialysis 1
Optimize Bladder Management First
The 2026 EAU Neuro-Urology guidelines emphasize that antibiotic treatment alone is insufficient 3. You must:
- Remove or change indwelling catheters if present
- Optimize bladder emptying (intermittent catheterization preferred)
- Remove bladder stones if present
- Do not treat asymptomatic bacteriuria in neurogenic bladder patients 3
Resistance Considerations
The IDSA 2025 guidelines recommend a four-step approach for cUTI 2:
- Severity: Paraplegic UTI is complicated by definition
- Resistance risk factors: Check prior urine cultures; if ESBL or AmpC producers suspected, cefepime remains appropriate but consider MIC values 4
- Patient factors: Assess renal function, prior antibiotic exposure
- Local antibiogram: If septic, choose antibiotic with ≥80% susceptibility 2
Important caveat: If KPC-producing organisms are suspected or previously isolated, do not use cefepime even if susceptibility testing suggests otherwise—clinical failures are documented 5. Use ceftazidime-avibactam or meropenem-vaborbactam instead 2.
Monitoring Requirements
- Baseline: Creatinine clearance, complete blood count, liver function tests
- During therapy:
When NOT to Use Cefepime
- Prior immediate hypersensitivity to cephalosporins or beta-lactams 1
- KPC-producing organisms (use novel beta-lactam/beta-lactamase inhibitor combinations instead) 2, 5
- Severe renal impairment without dose adjustment capability
- Asymptomatic bacteriuria (never treat in neurogenic bladder patients) 3
Alternative Considerations
If cefepime is inappropriate, IDSA 2025 guidelines recommend 2:
- Preferred alternatives: Piperacillin-tazobactam, fluoroquinolones (if local resistance <20%), carbapenems
- Novel agents for resistant organisms: Ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam
For recurrent UTI prevention in paraplegic patients, focus on bladder management optimization and consider weekly cycling antibiotic prophylaxis only in select cases with spinal cord injury 3. Avoid continuous long-term antibiotics 3.